Organization · Venture Capital
NG Bio
NG Bio is a London-based early-stage investor and venture builder focused on immunology and autoimmune diseases. The firm collaborates with pharmaceutical companies and research institutions to advance therapeutic development in the life sciences sector.
Overview
What NG Bio does
What NG Bio is
NG Bio is a London-based early-stage investor and venture builder focused on immunology and autoimmune diseases. The firm collaborates with pharmaceutical companies and research institutions to advance therapeutic development in the life sciences sector.
How it participates in the startup ecosystem
The current public profile supports funder and program host capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2020
- Approximate age
- About 6 years
- Structured capabilities
- Funder · Program host
- Last reviewed
- May 5, 2026
Official channels
Find NG Bio elsewhere
Open the official website or a supported primary organization account.
Capability profile
NG Bio as a funder
Investment thesis
NG Bio is focused on unlocking the power of the immune system to address autoimmune diseases and chronic inflammatory conditions, aiming to extend human health span and longevity.
Focus narrative
NG Bio invests primarily in the life sciences sector, focusing on therapeutic development for autoimmune diseases and chronic inflammatory conditions. The organization engages in venture creation and provides comprehensive support to portfolio companies, including financing strategies, growth planning, and exit strategies.
Value beyond capital
NG Bio adds value to its portfolio companies through hands-on venture creation, strategic financing support, and expertise in drug development planning. The team leverages their extensive experience in life sciences to guide companies from early-stage development through to successful exits.
Focus and fit
- Stages
- Pre-seed · Seed · Series A · Accelerator
- Regions
- Uk · Europe · Global
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 6
- Recorded notable exits
- Cellesce
Portfolio context
Notable portfolio companies include: LightOx: A platform for light-activated chemotherapy aimed at treating early-stage mouth cancers. Abselion: Provides biologic quantification at the benchtop using electrochemical detection. Cellesce: A bioprocess for scaling patient-derived organoids for high-throughput screening (acquired by Molecular Devices). Bastion Therapeutics: Develops proprietary GRIT platform technology to engineer Tregs for improved cell therapies. Mesenbio: Focuses on an extracellular vesicle platform to develop novel therapeutics for tissue regeneration in autoimmune diseases. Stealth Biotech: Engages in first-in-class therapeutics targeting novel factors and metabolites for autoimmune and immune-mediated inflammatory disorders.
Capability profile
NG Bio as a program host
Program thesis
NG Bio is focused on addressing harmful immune responses that contribute to major human diseases, aiming to extend human health span and longevity.
Focus narrative
NG Bio invests in life sciences, specifically targeting therapeutic development for autoimmune diseases and inflammation. The organization is dedicated to fostering innovation in this critical area of healthcare.
Availability
- Application state
- Not published
Focus and fit
- Stages
- Pre-seed · Seed · Seed+
- Regions
- EuropeUnited Kingdom
Alumni and track record
Alumni context
Notable portfolio companies include LightOx, a platform for light-activated chemotherapy; Abselion, which provides biologic quantification; Cellesce, known for scaling patient-derived organoids; Bastion Therapeutics, which develops Treg engineering technology; Mesenbio, focusing on therapeutics for tissue regeneration; and Stealth Biotech, targeting novel factors for immune-mediated disorders.
Common questions
What to know about NG Bio
Upseed classifies NG Bio under the Venture Capital organization type. Its current public profile includes funder and program host capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
May 5, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.